erlotinib hydrochloride has been researched along with pomalidomide in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 623 | 121 | 552 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | pomalidomide (IC50) |
|---|---|---|---|
| DNA damage-binding protein 1 | Homo sapiens (human) | 2.1 | |
| Protein cereblon | Homo sapiens (human) | 1.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belal, A; Ma, X; O Aboelez, M; Xiang, G | 1 |
1 other study(ies) available for erlotinib hydrochloride and pomalidomide
| Article | Year |
|---|---|
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Structure-Activity Relationship; Thalidomide | 2022 |